(Q45423590)

English

Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16197491%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16197491%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Hepatitis B virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16197491%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

A Marrone

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16197491%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

P Karayannis

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16197491%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

G Cirillo

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16197491%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

G Cesaro

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16197491%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

B Guerrera

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16197491%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

R Ricciotti

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16197491%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

E Miraglia del Giudice

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16197491%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

R Utili

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16197491%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

L E Adinolfi

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16197491%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

G Ruggiero

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16197491%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

language of work or name

0 references

publication date

1 October 2005

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16197491%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16197491%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16197491%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16197491%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

707-714

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16197491%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Durability of serologic response after lamivudine treatment of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

The complete nucleotide sequence of a pre-core mutant of hepatitis B virus implicated in fulminant hepatitis and its biological characterization in chimpanzees

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2005.02653.X

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45423590&oldid=1584887938"